Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Piperazin-1-Yl-Pyrimidine SCHEMBL893739 | 0.86 | ALDH1A1 (0.95) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| 2-Piperazin-1-Yl-Pyrimidine SCHEMBL169214 | 0.86 | ALDH1A1 (0.95) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| 2-Piperazin-1-Yl-Pyrimidine SCHEMBL27920766 | 0.84 | ALDH1A1 (0.91) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| 2-Piperazin-1-Yl-Pyrimidine SCHEMBL5375472 | 0.84 | ALDH1A1 (0.91) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| 2-Piperazin-1-Yl-Pyrimidine SCHEMBL924147 | 0.84 | ALDH1A1 (1.00) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| 2-Piperazin-1-Yl-Pyrimidine SCHEMBL27324991 | 0.84 | ALDH1A1 (0.91) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| 2-Piperazin-1-Yl-Pyrimidine SCHEMBL101561 | 0.84 | ALDH1A1 (1.00) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| 2-Piperazin-1-Yl-Pyrimidine SCHEMBL6861317 | 0.83 | ALDH1A1 (0.96) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| SCHEMBL1254909 | 0.79 | ALDH1A1 (0.81) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL27146448 | 0.78 | ALDH1A1 (0.85) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109893528-B | Use of koumine for treating lipid metabolism disorder and related diseases or symptoms thereof | 福建医科大学 | 2022-12-06 | — | — | CN | disclosed |
| US-20200113968-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | BAUSCH HEALTH IRELAND LTD (IE) | 2020-04-16 | — | — | US | disclosed |
| US-10597424-B2 | Agonists of guanylate cyclase and their uses | BAUSCH HEALTH IRELAND LIMITED (IE) | 2020-03-24 | — | — | US | disclosed |
| CN-105963676-B | Agonists of guanylate cyclase for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstones, obesity and other cardiovascular diseases | 药物协和股份有限公司 | 2020-02-18 | — | — | CN | disclosed |
| US-20190263861-A1 | AGONISTS OF GUANYLATE CYCLASE AND THEIR USES | JPMORGAN CHASE BANK, N.A. | 2019-08-29 | — | — | US | disclosed |
| US-20190262420-A1 | COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | SYNERGY PHARMACEUTICALS INC (US) | 2019-08-29 | — | — | US | disclosed |
| EP-2188293-B1 | 6-SUBSTITUTED SULFONYL AZABICYCLOÝ3.2.1¨OCTANES USEFUL TO INHIBIT 11 -HYDROXYSTEROID DEHYDROGENASE TYPE-1 | MERCK SHARP & DOHME (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10238712-B2 | Compositions useful for the treatment of gastrointestinal disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10118946-B2 | Agonists of guanylate cyclase and their uses | SYNERGY PHARMACEUTICALS INC. (US) | 2018-11-06 | — | — | US | disclosed |
| EP-3357502-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF COLON CANCER | Synergy Pharmaceuticals Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20020183305-A1 | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORPORATION | 2002-12-05 | — | — | US | disclosed |
| US-20020169134-A1 | Use of substituted azetidinone compounds for the treatment of sitosterolemia | SCHERING CORPORATION | 2002-11-14 | — | — | US | disclosed |
| US-20020151536-A1 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORPORATION | 2002-10-17 | — | — | US | disclosed |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | SCHERING CORPORATION | 2002-10-10 | — | — | US | disclosed |
| WO-2002058732-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) ACTIVATOR(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058685-A2 | COMBINATIONS OF NICOTINIC ACID AND DERIVATIVES THEREOF AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058733-A2 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058696-A2 | THE USE OF SUBSTITUTED AZETIDINONE COMPOUNDS FOR THE TREATMENT OF SITOSTEROLEMIA | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151536-A1 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | PPARG, PPARA, PPARD | ALDH1A1 1058/4885KDM4E 3879/4885CYP2D6 572/4885 |
| US-10238712-B2 | Compositions useful for the treatment of gastrointestinal disorders | GUCY1A1, TNF, GUCY1A2 | ALDH1A1 1700/4885KDM4E 4211/4885CYP2D6 3205/4885 |
| US-20190262420-A1 | COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GUCY1A1, TNF, GUCY1A2 | ALDH1A1 1700/4885KDM4E 4211/4885CYP2D6 3205/4885 |
| US-20200113968-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | GUCY1A1, GUCY1A2, GUCY1B2 | ALDH1A1 2674/4885KDM4E 2891/4885CYP2D6 4781/4885 |
| US-20020183305-A1 | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications | CYP46A1, APOB, SLC10A2 | ALDH1A1 1203/4885KDM4E 3999/4885CYP2D6 857/4885 |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | APOB, FABP2, CYP46A1 | ALDH1A1 2630/4885KDM4E 3462/4885CYP2D6 1441/4885 |
| US-20020169134-A1 | Use of substituted azetidinone compounds for the treatment of sitosterolemia | CYP46A1, CYP27A1, CYP51A1 | ALDH1A1 2090/4885KDM4E 2344/4885CYP2D6 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.